---
document_datetime: 2025-12-02 05:48:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/votrient.html
document_name: votrient.html
version: success
processing_time: 0.12169
conversion_datetime: 2025-12-28 10:11:28.357935
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Votrient

[RSS](/en/individual-human-medicine.xml/66560)

##### Authorised

This medicine is authorised for use in the European Union

pazopanib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Votrient](#news-on)
- [More information on Votrient](#more-information-on-votrient-723)
- [Related information](#related-information-724)
- [More information on Votrient](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Votrient. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Votrient.

Expand section

Collapse section

## What is Votrient?

Votrient is a medicine that contains the active substance pazopanib. It is available as tablets (200 mg; 400 mg).

## What is Votrient used for?

Votrient is used to treat adults with the following types of cancer:

- advanced renal-cell carcinoma, a type of kidney cancer. It is used in patients who have not received any previous treatment or in patients who have already been treated for their advanced disease with anticancer medicines called 'cytokines'. 'Advanced' means that the cancer has started to spread;
- certain forms of soft-tissue sarcoma, a type of cancer that develops from the soft, supporting tissues of the body. It is used in patients who have been previously treated with chemotherapy (medicines to treat cancer) because their cancer had spread, or in patients whose cancer has progressed within 12 months after receiving adjuvant or neoadjuvant therapy (treatment received after or before their main treatment).

The medicine can only be obtained with a prescription.

## How is Votrient used?

Treatment with Votrient should only be started by a doctor who has experience in giving anticancer medicines. The recommended dose is 800 mg once a day, but this may need to be reduced if the patient has side effects. Votrient should be taken with water but without food, at least one hour before or two hours after a meal.

In patients with moderate liver problems the dose should be reduced to 200 mg once a day. Votrient is not recommended in patients with severe liver problems.

## How does Votrient work?

The active substance in Votrient, pazopanib, is a protein-kinase inhibitor. This means that it blocks some specific enzymes known as protein kinases. These enzymes can be found in some receptors on the surface of cells that are involved in the growth and spread of cancer cells, such as 'VEGFR', 'PDGFR' and 'KIT'. By blocking these enzymes, Votrient can reduce the growth and spread of the cancer.

## How has Votrient been studied?

Votrient has been compared with placebo (a dummy treatment) in one main study involving 435 patients with advanced renal-cell carcinoma, some of whom had previously been treated with cytokines. Votrient has also been compared with placebo in a main study involving 369 patients with soft-tissue sarcoma whose disease had progressed during or following previous chemotherapy.

In all of the studies, the main measure of effectiveness was progression-free survival (how long the patients lived without their disease getting worse).

## What benefit has Votrient shown during the studies?

Votrient was more effective than placebo at treating advanced renal-cell carcinoma. On average, the patients who took Votrient lived for 9.2 months without their disease getting worse, compared with 4.2 months for the patients who took placebo.

Votrient was also more effective than placebo at treating soft-tissue sarcoma. On average, the patients who took Votrient lived for 20 weeks without their disease getting worse, compared with seven weeks for the patients who took placebo.

## What is the risk associated with Votrient?

The most common side effects with Votrient (seen in more than 1 patient in 10) include reduced appetite, dysgeusia (taste disturbances), hypertension (high blood pressure), diarrhoea, nausea (feeling sick), vomiting, pain, hair colour change, fatigue (tiredness), skin hypopigmentation (discolouration of the skin), exfoliative (flaky) rash, headache, stomatitis (inflammation of the lining of the mouth), decreased weight and increased blood levels of certain liver enzymes. For the full list of all side effects reported with Votrient, see the package leaflet.

Votrient must not be used in people who are hypersensitive (allergic) to pazopanib or any of the other ingredients.

## Why has Votrient been approved?

The CHMP considered that Votrient has been shown to be an effective medicine for patients with advanced renal-cell carcinoma and soft-tissue sarcoma, with a clinically relevant improvement in progression-free survival. The safety profile of Votrient is considered acceptable and generally manageable. Therefore, the Committee decided that Votrient's benefits are greater than its risks and recommended that it be given marketing authorisation.

Votrient was originally given 'conditional approval' because there was more evidence to come about the medicine, in particular in the treatment of renal-cell carcinoma. As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.

## Other information about Votrient:

The European Commission granted a conditional marketing authorisation valid throughout the European Union for Votrient on 14 June 2010. This was switched to a full marketing authorisation on 1 July 2013.

For more information about treatment with Votrient, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Votrient : EPAR - Summary for the public

English (EN) (87.91 KB - PDF)

**First published:** 08/07/2010

**Last updated:** 05/07/2013

[View](/en/documents/overview/votrient-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-602)

български (BG) (139.35 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/bg/documents/overview/votrient-epar-summary-public_bg.pdf)

español (ES) (110.89 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/es/documents/overview/votrient-epar-summary-public_es.pdf)

čeština (CS) (137.18 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/cs/documents/overview/votrient-epar-summary-public_cs.pdf)

dansk (DA) (108.37 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/da/documents/overview/votrient-epar-summary-public_da.pdf)

Deutsch (DE) (87.58 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/de/documents/overview/votrient-epar-summary-public_de.pdf)

eesti keel (ET) (109.56 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/et/documents/overview/votrient-epar-summary-public_et.pdf)

ελληνικά (EL) (140.42 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/el/documents/overview/votrient-epar-summary-public_el.pdf)

français (FR) (111.67 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/fr/documents/overview/votrient-epar-summary-public_fr.pdf)

italiano (IT) (108.93 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/it/documents/overview/votrient-epar-summary-public_it.pdf)

latviešu valoda (LV) (119.96 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/lv/documents/overview/votrient-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (111.72 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/lt/documents/overview/votrient-epar-summary-public_lt.pdf)

magyar (HU) (132.36 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/hu/documents/overview/votrient-epar-summary-public_hu.pdf)

Malti (MT) (138.63 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/mt/documents/overview/votrient-epar-summary-public_mt.pdf)

Nederlands (NL) (110.51 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/nl/documents/overview/votrient-epar-summary-public_nl.pdf)

polski (PL) (137.13 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/pl/documents/overview/votrient-epar-summary-public_pl.pdf)

português (PT) (109.37 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/pt/documents/overview/votrient-epar-summary-public_pt.pdf)

română (RO) (133.97 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/ro/documents/overview/votrient-epar-summary-public_ro.pdf)

slovenčina (SK) (135.29 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/sk/documents/overview/votrient-epar-summary-public_sk.pdf)

slovenščina (SL) (128.75 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/sl/documents/overview/votrient-epar-summary-public_sl.pdf)

Suomi (FI) (109.89 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/fi/documents/overview/votrient-epar-summary-public_fi.pdf)

svenska (SV) (110.53 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

05/07/2013

[View](/sv/documents/overview/votrient-epar-summary-public_sv.pdf)

Votrient : EPAR - Risk Management Plan

English (EN) (746.81 KB - PDF)

**First published:** 28/07/2021

**Last updated:** 25/04/2023

[View](/en/documents/rmp/votrient-epar-risk-management-plan_en.pdf)

## Product information

Votrient : EPAR - Product Information

English (EN) (563.31 KB - PDF)

**First published:** 08/07/2010

**Last updated:** 28/10/2025

[View](/en/documents/product-information/votrient-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-108)

български (BG) (750.21 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/bg/documents/product-information/votrient-epar-product-information_bg.pdf)

español (ES) (577.61 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/es/documents/product-information/votrient-epar-product-information_es.pdf)

čeština (CS) (693.5 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/cs/documents/product-information/votrient-epar-product-information_cs.pdf)

dansk (DA) (642.18 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/da/documents/product-information/votrient-epar-product-information_da.pdf)

Deutsch (DE) (602.07 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/de/documents/product-information/votrient-epar-product-information_de.pdf)

eesti keel (ET) (577.11 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/et/documents/product-information/votrient-epar-product-information_et.pdf)

ελληνικά (EL) (782.92 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/el/documents/product-information/votrient-epar-product-information_el.pdf)

français (FR) (718.41 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/fr/documents/product-information/votrient-epar-product-information_fr.pdf)

hrvatski (HR) (684.13 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/hr/documents/product-information/votrient-epar-product-information_hr.pdf)

íslenska (IS) (580.59 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/is/documents/product-information/votrient-epar-product-information_is.pdf)

italiano (IT) (720.64 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/it/documents/product-information/votrient-epar-product-information_it.pdf)

latviešu valoda (LV) (845.71 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/lv/documents/product-information/votrient-epar-product-information_lv.pdf)

lietuvių kalba (LT) (720.32 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/lt/documents/product-information/votrient-epar-product-information_lt.pdf)

magyar (HU) (657.18 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/hu/documents/product-information/votrient-epar-product-information_hu.pdf)

Malti (MT) (676.01 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/mt/documents/product-information/votrient-epar-product-information_mt.pdf)

Nederlands (NL) (618.56 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/nl/documents/product-information/votrient-epar-product-information_nl.pdf)

norsk (NO) (574.56 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/no/documents/product-information/votrient-epar-product-information_no.pdf)

polski (PL) (682.38 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/pl/documents/product-information/votrient-epar-product-information_pl.pdf)

português (PT) (577.82 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/pt/documents/product-information/votrient-epar-product-information_pt.pdf)

română (RO) (710.33 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/ro/documents/product-information/votrient-epar-product-information_ro.pdf)

slovenčina (SK) (705.95 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/sk/documents/product-information/votrient-epar-product-information_sk.pdf)

slovenščina (SL) (674.55 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/sl/documents/product-information/votrient-epar-product-information_sl.pdf)

Suomi (FI) (596.13 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/fi/documents/product-information/votrient-epar-product-information_fi.pdf)

svenska (SV) (561.91 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

28/10/2025

[View](/sv/documents/product-information/votrient-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000307790 28/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Votrient : EPAR - All Authorised presentations

English (EN) (11.44 KB - PDF)

**First published:** 08/07/2010

**Last updated:** 24/09/2012

[View](/en/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-922)

български (BG) (50.03 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/bg/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_bg.pdf)

español (ES) (102.71 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/es/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.42 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/cs/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.94 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/da/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.09 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/de/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.97 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/et/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (27 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/el/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_el.pdf)

français (FR) (17.26 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/fr/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (49.19 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/is/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.17 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/it/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (56.64 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/lv/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.46 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/lt/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.84 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/hu/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.51 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/mt/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (43.8 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/nl/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.9 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/no/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_no.pdf)

polski (PL) (36.29 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/pl/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.66 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/pt/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.98 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/ro/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (51.4 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/sk/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (76.6 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/sl/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.02 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/fi/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.1 KB - PDF)

**First published:**

08/07/2010

**Last updated:**

24/09/2012

[View](/sv/documents/all-authorised-presentations/votrient-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Votrient Active substance pazopanib International non-proprietary name (INN) or common name pazopanib Therapeutic area (MeSH) Carcinoma, Renal Cell Anatomical therapeutic chemical (ATC) code L01XE11

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Renal-cell carcinoma (RCC)**

Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

**Soft-tissue sarcoma (STS)**

Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.

Efficacy and safety have only been established in certain STS histological tumour subtypes.

## Authorisation details

EMA product number EMEA/H/C/001141 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 14/06/2010 Marketing authorisation issued 14/06/2010 Revision 32

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Votrient : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (255.73 KB - PDF)

**First published:** 28/10/2025

[View](/en/documents/procedural-steps-after/votrient-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Votrient : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (267.57 KB - PDF)

**First published:** 17/02/2011

**Last updated:** 28/10/2025

[View](/en/documents/procedural-steps-after/votrient-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Votrient-H-C-1141-P46-039 : EPAR - Assessment Report

Adopted

Reference Number: EMA/329579/2020

English (EN) (698.77 KB - PDF)

**First published:** 15/09/2020

[View](/en/documents/variation-report/votrient-h-c-1141-p46-039-epar-assessment-report_en.pdf)

Votrient-H-C-PSUSA-00002321-201910 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/438914/2020

English (EN) (149.68 KB - PDF)

**First published:** 19/08/2020

[View](/en/documents/scientific-conclusion/votrient-h-c-psusa-00002321-201910-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Votrient : EPAR - Scientific conclusions and grounds recommending the variation

Reference Number: EMA/712740/2015

English (EN) (63.92 KB - PDF)

**First published:** 27/10/2015

**Last updated:** 27/10/2015

[View](/en/documents/scientific-conclusion/votrient-epar-scientific-conclusions-and-grounds-recommending-variation_en.pdf)

Votrient-H-C-1141-II-0026 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/704739/2014

English (EN) (349.08 KB - PDF)

**First published:** 09/02/2015

**Last updated:** 09/02/2015

[View](/en/documents/variation-report/votrient-h-c-1141-ii-0026-epar-assessment-report-variation_en.pdf)

Votrient-H-C-1141-II-0007 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/408292/2012

English (EN) (987.5 KB - PDF)

**First published:** 17/08/2012

**Last updated:** 17/08/2012

[View](/en/documents/variation-report/votrient-h-c-1141-ii-0007-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Votrient

Adopted

Reference Number: EMA/CHMP/225896/2012

English (EN) (47.58 KB - PDF)

**First published:** 25/05/2012

**Last updated:** 25/05/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-votrient_en.pdf)

CHMP post-authorisation summary of positive opinion for Votrient

Adopted

Reference Number: EMA/CHMP/121263/2012

English (EN) (42.91 KB - PDF)

**First published:** 17/02/2012

**Last updated:** 17/02/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-votrient_en.pdf-0)

## Initial marketing authorisation documents

Votrient : EPAR - Public assessment report

English (EN) (613.2 KB - PDF)

**First published:** 08/07/2010

**Last updated:** 08/07/2010

[View](/en/documents/assessment-report/votrient-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Votrient

Adopted

Reference Number: EMA/CHMP/104905/2010 Rev. 1

English (EN) (52.8 KB - PDF)

**First published:** 18/02/2010

**Last updated:** 23/04/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-votrient_en.pdf)

#### News on Votrient

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2014) 25/04/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 May 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-may-2012) 25/05/2012

#### More information on Votrient

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu306382) on 29 June 2006. Votrient was withdrawn from the Community register of orphan medicinal products in April 2010 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### Related information

- [The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use](http://clincancerres.aacrjournals.org/content/17/21/6608.long)

#### More information on Votrient

- [Votrient - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/votrient)
- [EMEA-000601-PIP01-09-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000601-pip01-09-m06)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/10/2025

## Share this page

[Back to top](#main-content)